-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk Foundation Expands Carb-X Funding for Antimicrobial Resistance Products
Share
Listen to the news
01:42 AM EST, 11/18/2026 (MT Newswires) -- Novo Nordisk Foundation committed $60 million in funding to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or Carb-X, to advance the development of products for bacterial infections and antimicrobial resistance. The four-year funding builds on an initial $25 million grant provided to the non-profit public-private partnership in 2024, according to a Wednesday release. Novo Nordisk Foundation owns Novo Holdings, the controlling shareholder of drugmaker Novo Nordisk (NOVO-B.CO).
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending